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ORIGINAL ARTICLE
Analysis of Serum Cytokine Profile in Pemphigus
Sang Hee Lee, Won Jin Hong, Soo-Chan Kim
Department of Dermatology and Cutaneous Biology Research Institute, Gangnam Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea
Background: Pemphigus is a group of autoimmune blistering 
diseases affecting skin and mucous membranes. While pem-
phigus is an autoantibody mediated disease, the role of T 
cells and cytokines in the pathogenesis is being increasingly 
recognized. Objective: This study was conducted to observe 
alterations in the serum cytokine levels of patients with pem-
phigus vulgaris (PV), pemphigus foliaceous (PF), paraneo-
plastic pemphigus (PNP) and compare with bullous pemphi-
goid (BP) and healthy subjects. Methods: A total of 75 sub-
jects (28 PV, 13 PF, 7 PNP, 7 BP, and 20 healthy controls) 
were included, all patients in active disease state. Serum lev-
els of interferon (IFN)-γ, interleukin (IL)-4, IL-6, IL-17A, 
IL-10, tumor necrosis factor (TNF)-α, and IL-8 were meas-
ured by enzyme-linked immunosorbent assay. Results: The 
median concentration of IFN-γ was lower in PV and BP pa-
tients compared to control (0.77, 0.34 and 1.63 pg/ml, re-
spectively). IL-6 and IL-10 was significantly higher in PNP pa-
tients compared to control (4.92 and 0.24 pg/ml for IL-6, 0.86 
and ＜0.12 pg/ml for IL-10, respectively). IL-8 was increased 
significantly in PV and PNP patients compared with control 
(11.85, 31.5 and 8.31 pg/ml, respectively). For IL-4, IL-17A 
and TNF-α, no significant difference was observed between 
the five groups. Conclusion: The decreased level of IFN-γ in 
PV may imply suppressed Th1 response in the active disease 
stage. A Th2 predominant response is suggested in the active 
stage of PNP, with elevated serum levels of IL-6 and IL-10. 
Increased level of proinflammatory cytokine IL-8 is observed 
in the sera of PV and PNP patients. (Ann Dermatol 29(4) 438∼
445, 2017)
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INTRODUCTION
Pemphigus is a group of chronic autoimmune blistering 
diseases of skin and mucous membranes characterized by 
autoantibodies against desmogleins1. Pemphigus can be 
divided into four major subtypes; pemphigus vulgaris 
(PV), pemphigus foliaceus (PF), paraneoplastic pemphigus 
(PNP) and immunoglobulin (Ig)A pemphigus2. Each sub-
type can be distinguished by the target of the specific au-
toantibodies or by the location of blister formation. PV is 
associated with autoantibodies against desmoglein (Dsg)1 
and 3, while PF has autoantibodies directed to Dsg1. PNP, 
almost always associated with an underlying neoplasm, is 
characterized by the autoantibodies against plakin family 
proteins such as desmoplakin, envoplakin, and periplakin, 
as well as Dsg1 and Dsg33. 
The production of pathogenic antibodies is key to the de-
velopment of blisters in pemphigus, and many immuno-
logical steps are required prior to autoantibody production. 
Active mouse model experiment revealed that both Dsg- 
specific T and B cells are necessary for the production of 
pathogenic autoantibodies4, and the role of T cell subsets 
and their cytokines is being increasingly recognized. Cyto-
kines can be categorized as Th1 type (interleukin [IL]-2, 
IL-12, IL-18, interferon [IFN]-γ), Th2 type (IL-4, IL-5, IL-6, 
IL-10, IL-13), Th17 type (IL-17, IL-22, IL-23), Treg type 
(IL-10, transforming growth factor [TGF]-β) and proin-
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flammatory cytokines (IL-1, IL-8, tumor necrosis factor 
[TNF]-α). There have been several studies aiming to iden-
tify the presence of these mediators in serum, perilesional 
skin, and blister fluid of pemphigus5. The majority of pre-
vious studies have suggested Th2 pathway upregulation, 
with increased serum levels of IL-4, IL-6 and IL-106. Th1 
pathway on the other hand, has shown contradictory 
results. There are both respectable number of studies 
showing increased and decreased levels of IFN-γ and 
IL-2, as well as no significant differences in Th1 cytokine 
levels compared to a control group5. Only a limited num-
ber of studies are available regarding the Th17 pathway in 
pemphigus, and Th17 cells were increased in the skin le-
sions of PV in one study7. The results of studies on Treg 
cells in pemphigus are also controversial, but primarily 
demonstrate a lack of significant difference in the hallmark 
regulatory cytokine, TGF-β, in patients versus control 
groups5. Proinflammatory cytokines were also studied, 
which in majority of results showed elevated level of 
TNF-α and IL-68,9, several results of elevated IL-110,11 and 
two reports of elevated IL-8 in the PV blister fluid and se-
rum, respectively12,13.
So far, cytokine studies in pemphigus have had varied re-
sults, further complicating our understanding of the dis-
ease process. Therefore, this study was conducted to as-
sess the level of cytokines in the serum from patients af-
fected with PV, PF, PNP and compare with bullous pem-
phigoid (BP) and healthy subjects. 
MATERIALS AND METHODS
Study design
To evaluate the different T cell subsets involved in the 
pathogenesis of pemphigus, Th1 cytokine IFN-γ, Th2 cy-
tokine IL-4, IL-6 and IL-10, Th17 cytokine IL-17A, regu-
latory T cell cytokine IL-10 and proinflammatory cytokines 
TNF-α and IL-8 were measured. Serum levels of cyto-
kines were measured in the individuals of five groups; PV, 
PF, PNP, BP and healthy individuals. This study was ap-
proved by the Institutional Review Board of Gangnam 
Severance Hospital, Yonsei University (IRB no. 320150186).
Patients
The sample collection for this study was conducted on pa-
tients who visited the Department of Dermatology at 
Gangnam Severance Hospital, Seoul, Korea between 2006 
and 2013. Serum samples were obtained from 28 PV pa-
tients, 13 PF patients, 7 PNP patients, 7 BP patients, and 
20 healthy subjects. All the patients enrolled in the study 
had clinically active stage of the disease. Active stage was 
defined as the de novo development of blisters/erosions 
on previously unaffected or healed up sites of mucocuta-
neous surfaces. Serum was collected on the patient’s first 
visit or at the time of acute flare in the disease course. The 
clinical diagnosis of PV, PF and BP was confirmed by his-
topathologic findings, direct immunofluorescence (DIF) 
examination and/or the detection of serum autoantibodies 
by indirect immunofluorescence (IIF) examination. PNP 
patients were diagnosed using the following criteria14: (i) 
clinical features, including the presence of severe mucosal 
involvement or polymorphous cutaneous eruption; (ii) 
characteristic histological features of the skin or mucosal 
eruption (interface dermatitis, acantholysis and apoptotic 
keratinocytes); (iii) the presence of autoantibodies de-
tected in DIF or IIF studies; (iv) detection of anti-plakin or 
anti-Dsg autoantibodies in immunoblotting or Dsg en-
zyme-linked immunosorbent assay (ELISA); and (v) the 
presence of associated neoplasm. Diagnosis of PNP re-
quired four of five criteria, including criteria (i) and (ii).
ELISA
Cytokines were analyzed using a commercial assay system 
of immunoassay kits and panels (Millipore MILLIPLEX 
Human Cytokine Panel I Premixed 7 Plex [HCYTOMA-
G60K07]) using a magnetic bead-based immunoassay kit 
(Luminex 200; Luminex Corp., Austin, TX, USA). Serum 
samples were incubated with antibody-coated capture 
beads overnight at 4oC. Washed beads were further in-
cubated with biotin-labeled anti-human cytokine anti-
bodies, followed by streptavidin–phycoerythrin incubation. 
Samples were read on a Luminex 200 reader with xPOTENT 
software. The standard curves of known concentrations of 
recombinant human cytokines were used to convert fluo-
rescence units to concentrations (pg/ml). To calculate the 
cytokine concentrations in the serum samples, we ana-
lyzed the median fluorescent intensity data using a 5-pa-
rameter logistic or spline curve-fitting method.
Statistical analyses
Owing to the limited number of subjects, the results of cy-
tokines are expressed by employing median values and 
25%∼75% ranges15. For the comparison of the five differ-
ent groups (PV, PF, PNP, BP and control), the Kruskal–
Wallis test was performed at first. Mann-Whitney tests 
were additionally performed in the parameters which 
showed significant difference in the Kruskal-Wallis test 
(IFN-γ, IL-6, IL-10 and IL-8). Differences were defined as 
statistically significant at p-value ＜0.05. The reported 
p-values were not adjusted for multiple testing. Statistical 
analyses were performed using commercial software (SAS 
ver. 9.2; SAS Institute, Cary, NC, USA).
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Table 2. Cytokine levels detected in the serum of PV, PF, PNP, BP patients and normal controls
　Cytokine Control PV PF PNP BP
IFN-γ 1.63 (1.07, 6.04) 0.77* (0.17, 2.50) 1.2 (0.34, 1.98) 1.72 (0.85, 12.20) 0.34* (0.17, 5.77)
IL-4 1.86 (1.86, 1.86) 1.86 (1.86, 1.86) 1.86 (1.86, 1.86) 1.86 (1.86, 1.86) 1.86 (1.86, 1.86)
IL-6 0.24 (0.24, 0.24) 0.24 (0.24, 0.24) 0.24 (0.24, 0.24) 4.92* (0.24, 18.88) 0.24 (0.24, 1.82)
IL-17A 0.06 (0.06, 1.27) 0.06 (0.06, 0.35) 0.06 (0.06, 0.06) 0.06 (0.06, 0.27) 0.06 (0.06, 0.06)
IL-10 0.12 (0.12, 0.51) 0.12 (0.12, 1.66) 0.12 (0.12, 3.60) 0.86* (0.55, 127.43) 0.12 (0.12, 8.38)
TNF-α 7.16 (5.88, 8.97) 10.21 (7.32, 12.67) 8.58 (6.52, 10.41) 14.53 (0.49, 31.76) 5.78 (5.00, 11.37)
IL-8 8.28 (5.84, 10.92) 11.85* (8.97, 20.42) 8.97 (3.22, 10.94) 31.5* (10.59, 94.11)   5.8 (4.72, 14.13)
Values are presented as median (25th and 75th percentile). All cytokine levels are expressed as picograms per milliliter. PV: pemphigus
vulgaris, PF: pemphigus foliaceous, PNP: paraneoplastic pemphigus, BP: bullous pemphigoid, IFN: interferon, IL: interleukin, TNF:
tumor necrosis factor. *Data statistically significant compared to control group.
Table 1. Baseline characteristics of study population 
Case Number (n=75) Male Female Age (yr)
PV 28 13 15 55.28±14.10 (24∼83)
PF 13 7 6 51.57±18.97 (15∼81)
PNP 7 4 3 45.00±2.19 (43∼47)
BP 7 5 2 69.71±14.55 (49∼85)
Control 20 9 11 24.15±3.62 (17∼29)
Values are presented as number only or mean±standard deviation (range). PV: pemphigus vulgaris, PF: pemphigus foliaceous, PNP: 
paraneoplastic pemphigus, BP: bullous pemphigoid.
RESULTS
A total of 75 subjects (28 PV, 13 PF, 7 PNP, 7 BP, and 20 
healthy controls) were studied. The mean±standard devi-
ation of age was 55.28±14.10 years (range, 24∼83 years) 
in PV patients, 51.57±18.97 (range, 15∼81 years) in PF 
patients, 45.00±2.19 (range, 43∼47 years) in PNP pa-
tients, 69.71±14.55 (range, 49∼85 years) in BP patients 
and 24.15±3.62 (range, 17∼29 years) in the healthy con-
trols, respectively, as shown in Table 1. 
Cytokine measurements in the five groups are shown in 
Table 2 and Fig. 1. Cytokines which showed significant 
difference in the Kruskal-Wallis test was IFN-γ, IL-6, IL-10 
and IL-8 (p=0.01, 0.019, 0.039 and 0.004, respectively). 
The median concentration of the Th1 cytokine, IFN-γ, 
was significantly decreased in PV and BP when compared 
to normal control (0.77 pg/ml in PV, 0.34 pg/ml in BP and 
1.63 pg/ml in the control group; p=0.0054 and p=0.035, 
respectively). When comparing PV with BP, serum con-
centration of IFN-γ was not significantly different be-
tween the two groups (p=0.4302). 
The median concentration of IL-6 was significantly higher 
in patients with PNP, compared to healthy control (4.92 
pg/ml in PNP, 0.24 pg/ml in control; p=0.0194). IL-6 was 
detectable in 5 of 7 PNP sera, which all showed higher 
concentration than the median value of normal control sera.
Higher concentrations of IL-10 were observed in the PNP 
group (0.86 pg/ml) compared to the normal control group 
(p=0.0046). IL-10 levels were higher than the median val-
ue of normal controls in all seven serum samples from the 
PNP group. The median concentration of IL-10 was not 
significantly different between the normal controls and pa-
tients with PV, PF or BP (＜0.12 pg/ml in PV, PF, BP and 
control). 
Serum levels of IL-8 were significantly higher in the PV 
and PNP groups than in normal controls (11.85 pg/ml in 
PV, 31.5 pg/ml in PNP, 8.31 pg/ml in controls; p=0.0227 
and p=0.0322, respectively). 
Serum levels of Th2 cytokine IL-4 were below the de-
tection limits (＜1.86 pg/ml) in all but four samples, which 
included one patient with BP and three healthy controls. 
There were no significant differences in IL-17A, the Th17 
cytokine, between the five groups. TNF-α also did not 
differ significantly between the five groups. When com-
paring PV sera with PF sera, none of the cytokines showed 
significant difference (data not shown). 
DISCUSSION
In pemphigus, it is postulated that autoreactive T cells are 
involved in the induction and maintenance of autoanti-
body production4,16,17. It thus follows that cytokines are 
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Fig. 1. Dot plots of cytokine levels detected in the serum of pemphigus vulgaris (PV), pemphigus foliaceous (PF), paraneoplastic 
pemphigus (PNP), bullous pemphigoid (BP) patients and normal controls. The horizontal bar for each group indicates the median 
value. IFN: interferon, IL: interleukin. *p＜0.05, **p＜0.01.
likely to be key players in the coordination of the cellular 
and humoral responses in pemphigus. The present study 
of serum cytokine analysis in pemphigus showed a de-
crease of IFN-γ in PV and BP, an increase of IL-6 and 
IL-10 in PNP, and an increase of IL-8 in PV and PNP when 
compared to healthy controls.
There have been studies reporting an imbalance of 
Th1/Th2 response in pemphigus, which can ultimately re-
sult in complex and severe impairment of immune func-
tion6. Once a naïve T cell differentiate to Th2 cell, specific 
transcription factors such as GATA-3 and c-maf are acti-
vated, which in turn activate the Th2 cytokines while 
down-regulating factors necessary to generate Th1 re-
sponse18,19. In the majority of previous studies, involve-
ment of Th2 pathway has been demonstrated in the patho-
genesis of pemphigus and as a consequence, down-regu-
lation of Th1 pathway is to be anticipated in disease5. 
However, there are a considerable number of studies 
showing increased and decreased levels of IFN-γ, as well 
as studies showing no significant difference compared to 
control group5. The reason for the variation might poten-
tially be due to small number of samples included in some 
of the studies20, and the varied timing of serum collection 
during the disease course21. Our result of IFN-γ was sig-
nificantly decreased in PV compared to control, although 
it was not accompanied with the IL-4 increase. A previous 
study by Veldman et al.21 showed that peripheral Dsg3-re-
active Th1 cells varied according to the clinical activity of 
PV. Sera in our study was collected in the active stage of 
disease, both acute and chronic, and our result suggest 
that the Th1 pathway may be suppressed in the active 
stage of PV6,22. In comparison of the PV sera with BP sera, 
which also showed decreased level of IFN-γ compared to 
control, there was no significant difference. In contrast to 
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our finding, several studies reported increased level of 
IFN-γ in the serum and blister fluid of BP23-25. On the oth-
er hand, Giomi et al.26 speculated that an early stage of BP 
can be characterized by an initial Th0/Th2-like response 
(IL-4, IL-5, low levels of IFN-γ), and a chronic Th1-skewed 
phase would follow. Studies in the intermediate phase 
would be presented by a mixed Th1/Th2 expression, this 
also highlighting the different cytokine profile according 
to disease phases. The decrease in IFN-γ in the BP group 
seen in the present study might represent suppression of 
the Th1 pathway in the active disease stage. 
Even though there are some good evidences that PV is a 
Th2-mediated disease and several studies have demon-
strated an increase in Th2 cytokines6,25,27, we did not ob-
serve any significant differences in IL-4 between patient 
groups and healthy control. Although far less common, re-
ports exist documenting reduced or no significant differ-
ence in the IL-4 level compared to control as shown in our 
study15,20. However, it is now generally accepted that IL-4 
has an important role in pemphigus pathogenesis and 
there is limitation in the interpretation of our result, because 
most samples were under the detection limit for IL-4; 74 
out of 78 sera were below the detection limit (＜1.86 
pg/ml). 
Th17 cells have been implicated in the initiation and pro-
gression of many inflammatory and autoimmune diseases 
such as autoimmune encephalitis, inflammatory bowel 
disease and psoriasis28. In pemphigus, on the other hand, 
there is only a limited number of data examining its role. 
Arakawa et al.7 found Th17 cells in skin lesions of patients 
with PV, but did not find a significant correlation between 
the Th17 cells and disease activity or anti-Dsg3 antibody 
titers. Giordano and Sinha5 mentioned that they had un-
published data showing an increase in IL-17A levels in PV 
compared to controls. However, we did not find any sig-
nificant difference of IL-17A levels between the control 
and patient groups. Regarding the fact that Th17 cells in 
lesional skin neither correlated with autoantibody level 
nor with the clinical severity of PV, and the fact that our 
study showed no significant difference in serum IL-17A 
level, the role of Th17 cells in pemphigus still remain 
questionable and require further investigation. 
Regulatory T cells play a crucial role in modulating pe-
ripheral tolerance and preventing autoimmunity. In pem-
phigus, a relative decrease in Treg function may be in-
volved in the pathogenesis. Data reported on Treg cells 
and their cytokines, TGF-β and IL-10, are quite varied in 
pemphigus29. Cytokine studies published so far have dem-
onstrated a lack of significant variation in TGF-β between 
PV and control15,17. As for IL-10, a majority of published 
studies reported an increase in serum IL-10 in PV pa-
tients5. IL-10 does play a significant role in the Treg path-
way, but it is also associated with the Th2 pathway, and 
some authors assumed this increase represents an acti-
vated Th2 pathway5. However in the present study, serum 
IL-10 values in PV, PF, and BP did not differ from control. 
In PNP, on the other hand, IL-10 was elevated compared 
to control group. IL-10 is an anti-inflammatory cytokine 
with a role in preventing inflammatory and autoimmune 
pathologies, but it is also a potent B cell stimulator that en-
hances activation, proliferation, and differentiation of B 
cells30. A recent study of PV suggested a model for the 
role of IL-10 in the active disease state31. It is suggested 
that in active PV, IL-10 favors class switch to the classic 
PV autoantibody subclass IgG4, and promotes B cell dif-
ferentiation into antibody secreting cells which results in 
higher anti-Dsg3 antibody concentrations. B cells exhibit-
ing regulatory functions (Bregs)32 are defective in active 
PV with reduced IL-10 secretion and inability to suppress 
CD4+T cell responses, which perpetuates the auto-
immune reaction. In PNP, no data regarding IL-10 have 
been published, but our result of increased IL-10 might al-
so reflect the autoimmune stimulating effects of IL-10 in 
the disease pathogenesis. 
IL-6 was also significantly increased in PNP compared to 
healthy control, consistent with previous findings. IL-6 is 
known to promote differentiation and maturation of B 
cells, and drive immunoglobulins production. Markedly 
elevated serum IL-6 levels have been demonstrated in a 
majority of PNP patients33. Furthermore, in a subset of tu-
mors associated with PNP, such as non-Hodgkin lympho-
ma, chronic lymphocytic leukemia and Castleman’s dis-
ease, it has been observed that the tumor cells secrete 
large amounts of IL-6 in vitro34. With our result further 
supporting the hypothesis, IL-6 seems to contribute to the 
induction of autoantibodies, playing an important role in 
autoimmune pathology of PNP. 
It may be possible to speculate that Th2 pathway is upre-
gulated in PNP, with both IL-6 and IL-10 increased in the 
sera of PNP patients. IL-6 and IL-10 are also the cytokines 
of Th2 pathway, as well as the classic Th2 cytokine IL-4, 
and it is known that the Th2 cells are involved in the de-
velopment of humoral immunity. As extremely limited 
number of cytokine studies are available in PNP, a com-
prehensive set of cytokines including IL-5 and IL-13 needs 
to be further examined to clarify our result.
Serum levels of IL-8 were significantly higher in PV and 
PNP compared to control. IL-8 induces chemotaxis in tar-
get cells, primarily neutrophils, and is a product of kerati-
nocytes and dermal cells such as fibroblasts, endothelial 
cells and macrophages. An immunohistochemical study of 
pemphigus showed intensive expression of IL-8 co-lo-
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calized with in vivo bound IgG in the upper epidermis 
where acantholysis took place35. Baroni et al.12 also dem-
onstrated a high IL-8 value in the blister fluid of pemphi-
gus patients, and Keskin et al.13 showed increased serum 
level of IL-8 compared to control. IL-8 has not been stud-
ied in PNP before, but increased serum level of IL-8 might 
have a role in recruitment of polymorphonuclear leuko-
cytes to the skin lesion of PNP. However, neutrophil in-
filtration is not a prominent feature in PNP, and also, the 
small sample size of PNP sera in our study precludes a de-
finitive conclusion. Another possible explanation for in-
creased IL-8 in PV and PNP is that it may not be a cause 
but a result of the disease, i.e., an inflammatory response 
following the damaged epithelial barrier. It has been 
shown that disruptions to skin such as trauma, irritation 
and ultraviolet B radiation induce IL-8 in lesional skin36-39. 
Our study was conducted with sera collected in the active 
stage, and multiple blisters and erosions may trigger the 
release of various inflammatory cytokines including IL-8. 
However, it should be noted that IL-8 was not increased in 
PF or BP, and further detailed studies are still needed to 
identify the precise role of IL-8 in different pemphigus 
groups.
TNF-α has been widely studied in pemphigus, with ma-
jority of studies showing an increase in the serum and in 
the blister fluid5. It has been shown in a previous study 
that serum levels of TNF-α correlate with disease severity 
in PV15. There were also reports of anti-TNF-α drugs with 
certain efficacy in PV40. On the contrary, a case report of 
spontaneous development of PV in a psoriatic patient 
upon infliximab was noted41. Also, a recently published 
pilot study comparing etanercept versus placebo in 8 pa-
tients with PV failed to find significant therapeutic efficacy 
in the etanercept group42. A double-blind, placebo-con-
trolled trial of infliximab with prednisone versus pre-
dnisone alone showed that infliximab therapy was not ef-
fective for the treatment of patients with PV43. In our 
study, TNF-α level in the pemphigus serum failed to 
show any significant difference from the control serum. 
While a strong increase of TNF-α was observed in the 
most of the previous studies, heterogeneous response of 
anti-TNF-α drugs in pemphigus patients imply a complex 
mechanism of this cytokine in the disease pathogenesis. 
When comparing PV with PF, none of the cytokines we 
evaluated were significantly different between the two 
groups. Although PF and PV differ in their antigens and 
thus represent distinct clinical entities, concerning the 
pathogenic role of cytokines no major differences appear 
to exist between the two diseases.
The strength of our study is that we included a relatively 
large number of patients from a single center, and we ana-
lyzed the serum cytokine levels of PNP, which has not 
been studied much due to its lower incidence compared 
to other pemphigus subtypes. In addition, studies regard-
ing Th17 response in pemphigus are extremely limited, 
and our data provides additional information in under-
standing the Th17 pathway in pemphigus. However, our 
study also has several limitations. The age and sex dis-
tributions are not homogeneous among the study group 
which can potentially have influenced the results. Also, 
the number of PNP and BP patient included in this study 
is relatively small and further studies with more patients 
will be needed in the future. Although the patients in-
cluded in the study were in the active disease state with 
uncontrolled development of the blisters, their hetero-
genous treatment history including different doses of sys-
temic corticosteroid and immunosuppressants may have 
influenced the serum cytokine levels. 
In conclusion, our data shows decreased level of IFN-γ in 
PV, which may imply suppressed Th1 response in the ac-
tive disease stage. A Th2 predominant response is sug-
gested in the active stage of PNP, with elevated serum lev-
els of IL-6 and IL-10. Increased level of proinflammatory 
cytokine IL-8 is observed in the sera of PV and PNP 
patients. Serum IL-17A levels did not differ significantly 
between the five groups. We think our study will be of a 
valuable reference data for the future studies of T cells and 
cytokines in pemphigus. 
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